Comparing Biosimilar Growth in the US, Germany, and Switzerland
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
News
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.
Rheum Manpower Needs - More Programs! (12.2.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Rheum Drugs & IDSA Guidelines to Treat COVID-19
The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX.
Just Can’t Get Enough of Hydroxychloroquine
When it comes to hydroxychloroquine dosing, issues on efficacy, toxicity and therapeutic thresholds may affect the optimal use of this important drug. Following are three abstracts presented during the meeting that address these topics.
Steroid injections worsen knee arthritis
EurekAlert!
Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
ACR22 Takeaways: Pre-RA, Lupus, PsA and AS
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways.
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
How Underweight Women Can Reduce Hip Fracture Risk
EurekAlert!
